Unknown

Dataset Information

0

A relA-dependent regulatory cascade for auto-induction of microbisporicin production in Microbispora corallina.


ABSTRACT: Microbisporicin is a potent type I lantibiotic produced by the rare actinomycete Microbispora corallina that is in preclinical trials for the treatment of infections caused by methicillin-resistant isolates of Staphylococcus aureus (MRSA). Analysis of the gene cluster for the biosynthesis of microbisporicin, which contains two unique post-translationally modified residues (5-chlorotryptophan and 3, 4-dihydroxyproline), has revealed an unusual regulatory mechanism that involves a pathway-specific extracytoplasmic function sigma factor (MibX)/anti-sigma factor (MibW) complex and an additional transcriptional regulator MibR. A model for the regulation of microbisporicin biosynthesis derived from transcriptional, mutational and quantitative reverse transcription polymerase chain reaction analyses suggests that MibR, which contains a C-terminal DNA-binding domain found in the LuxR family of transcriptional activators, functions as an essential master regulator to trigger microbisporicin production while MibX and MibW induce feed-forward biosynthesis and producer immunity. Moreover, we demonstrate that initial expression of mibR, and thus microbisporicin production, is dependent on the ppGpp synthetase gene (relA) of M.?corallina. In addition, we show that constitutive expression of either of the two positively acting regulatory genes, mibR or mibX, leads to precocious and enhanced microbisporicin production.

SUBMITTER: Fernandez-Martinez LT 

PROVIDER: S-EPMC4973701 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A relA-dependent regulatory cascade for auto-induction of microbisporicin production in Microbispora corallina.

Fernández-Martínez Lorena T LT   Gomez-Escribano Juan P JP   Bibb Mervyn J MJ  

Molecular microbiology 20150529 3


Microbisporicin is a potent type I lantibiotic produced by the rare actinomycete Microbispora corallina that is in preclinical trials for the treatment of infections caused by methicillin-resistant isolates of Staphylococcus aureus (MRSA). Analysis of the gene cluster for the biosynthesis of microbisporicin, which contains two unique post-translationally modified residues (5-chlorotryptophan and 3, 4-dihydroxyproline), has revealed an unusual regulatory mechanism that involves a pathway-specific  ...[more]

Similar Datasets

| S-EPMC3133186 | biostudies-literature
| S-EPMC6191445 | biostudies-literature
| PRJDB10021 | ENA
| S-EPMC2955141 | biostudies-literature
| S-EPMC5766588 | biostudies-literature
| S-EPMC3379538 | biostudies-literature
2020-03-20 | MSV000085123 | GNPS
| S-EPMC2984483 | biostudies-literature